Science 37 Becomes First Site for At-Home Clinical Trials

- Science 37 was founded in 2014 by Noah Craft and Belinda Tan and was acquired by eMed, LLC in March 2024. The company's technology platform, known as the Network Oriented Research Assistant (NORA), facilitates "site-less" trials through features like video chat, data collection, and electronic consent. - The global market for decentralized clinical trials (DCTs) was valued at USD 8.6 billion in 2024 and is projected to grow to USD 29.7 billion by 2034, with a compound annual growth rate of 13.3%. This growth is largely driven by the adoption of digital tools like telemedicine and wearable devices. - In a recent Phase 3 trial for primary biliary cholangitis, Science 37 was responsible for enrolling 47% of the U.S. study participants. The company has undergone three successful FDA inspections within the last two years, each resulting in a "No Action Indicated" (NAI) classification. - The FDA's final guidance on decentralized trials, issued in September 2024, focuses on implementing "decentralized elements" such as telehealth or in-home visits, rather than classifying entire trials as decentralized. This guidance aims to reduce participant burden and increase access for underrepresented populations. - For consumer health apps, data privacy regulations extend beyond HIPAA. State laws like Washington's My Health My Data Act and California's Consumer Privacy Act (CCPA) often apply to data collected directly from consumers, which may not be covered by HIPAA. - AI and machine learning are increasingly used in decentralized trials to analyze large datasets from sources like wearables and electronic patient-reported outcomes. This technology can help in predicting patient responses, identifying potential adverse events, and optimizing trial design. - Wearable devices play a significant role in DCTs by enabling continuous, real-time data collection on metrics like heart rate, activity levels, and sleep patterns, which can reduce the need for frequent site visits. This approach helps to lessen patient recall bias and can lead to higher adherence rates in studies. - The biohacking community utilizes technological tools like Oura Ring, WHOOP, and continuous glucose monitors for data-driven health optimization. This aligns with the decentralized trial model's use of wearables to gather real-time physiological data for research.